Katherine Sommer
YOU?
Author Swipe
View article: Real-World Safety and Efficacy of 156 U – 195 U OnabotulinumtoxinA in Adults With Chronic Migraine: Results From the REPOSE Study
Real-World Safety and Efficacy of 156 U – 195 U OnabotulinumtoxinA in Adults With Chronic Migraine: Results From the REPOSE Study Open
View article: Characterizing barriers to care in migraine: multicountry results from the Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) study
Characterizing barriers to care in migraine: multicountry results from the Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) study Open
NA.
View article: Characterizing neck pain during headache among people with migraine: Multicountry results from the Chronic Migraine Epidemiology and Outcomes – International (CaMEO‐I) cross‐sectional study
Characterizing neck pain during headache among people with migraine: Multicountry results from the Chronic Migraine Epidemiology and Outcomes – International (CaMEO‐I) cross‐sectional study Open
Objective To assess the prevalence and impact of neck pain during headache among respondents with migraine in the multicountry Chronic Migraine Epidemiology and Outcomes – International (CaMEO‐I) Study. Background Neck pain among individua…
View article: Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials
Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials Open
Objective To characterize the long‐term (56‐week) benefits of continuous onabotulinumtoxinA treatment response in individuals with chronic migraine (CM) who achieved reduction to <15 headache days/month with treatment. Background There are…
View article: OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study – CORRIGENDUM
OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study – CORRIGENDUM Open
An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the 'Save PDF' action button.
View article: Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study
Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study Open
Background Individuals using onabotulinumtoxinA as a preventive migraine treatment often use acute treatments for breakthrough attacks. Data on real-world effectiveness of the small-molecule calcitonin gene–related peptide (CGRP) receptor …
View article: 2606 PREDICT: PREEMPT fixed-dose, fixed-site and follow the pain
2606 PREDICT: PREEMPT fixed-dose, fixed-site and follow the pain Open
Objective Analyse the real-world effectiveness and safety of 155U, 156–195U and 195U onabotulinumtoxinA in patients with chronic migraine (CM) from the PREDICT study. Methods PREDICT (NCT02502123) was a Canadian 2-year, prospective, observ…
View article: Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) Study: Methods and multi-country baseline findings for diagnosis rates and care
Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) Study: Methods and multi-country baseline findings for diagnosis rates and care Open
Background The Chronic Migraine Epidemiology and Outcomes-International study provides insight into people with migraine in multiple countries. Methods This cross-sectional, observational, web-based cohort study was conducted in Canada, Fr…
View article: CJN volume 50 issue 3 Cover and Front matter
CJN volume 50 issue 3 Cover and Front matter Open
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
View article: Effectiveness and Safety of Chronic Migraine Preventive Treatments: A Systematic Literature Review
Effectiveness and Safety of Chronic Migraine Preventive Treatments: A Systematic Literature Review Open
View article: CJN volume 49 issue 4 Cover and Front matter
CJN volume 49 issue 4 Cover and Front matter Open
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
View article: OnabotulinumtoxinA Reduces Health Resource Utilization in Chronic Migraine: PREDICT Study
OnabotulinumtoxinA Reduces Health Resource Utilization in Chronic Migraine: PREDICT Study Open
Background: PREDICT was a Canadian, multicenter, prospective, observational study in adults naïve to onabotulinumtoxinA treatment for chronic migraine (CM). We descriptively assess health resource utilization, work productivity, and acute …
View article: Practical Insights on the Identification and Management of Patients with Chronic Migraine
Practical Insights on the Identification and Management of Patients with Chronic Migraine Open
View article: OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study
OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study Open
Background: The PREDICT study assessed real-world, long-term health-related quality of life in adults with chronic migraine (CM) receiving onabotulinumtoxinA. Methods: Canadian, multicenter, prospective, observational study in adults naïve…
View article: Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study
Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study Open
View article: An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study
An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study Open
View article: Autonomic Cross-Innervation in Patients With Neurofibromatosis Type 2: Frey Syndrome and Unilateral Epiphora With Rhinorrhea
Autonomic Cross-Innervation in Patients With Neurofibromatosis Type 2: Frey Syndrome and Unilateral Epiphora With Rhinorrhea Open
The authors present 2 cases of cross-innervation in patients with neurofibromatosis type 2. In the first case, an iodine test was performed to demonstrate Frey syndrome in a 28-year-old female with neurofibromatosis type 2 who developed sy…
View article: Social skills in children with RASopathies: a comparison of Noonan syndrome and neurofibromatosis type 1
Social skills in children with RASopathies: a comparison of Noonan syndrome and neurofibromatosis type 1 Open
Amidst efforts to support social skill development among children and adolescents with RASopathies, neuropsychological correlates such as social language competence, attention, and behavioral self-regulation could be important targets of i…